Pakistan Science Abstracts
Article details & metrics
No Detail Found!!
A study of Serum Visfatin Levels in Obese and Non-obese Primary Hypertensive Subjects.
Author(s):
1. Naghmana Lateef: PGMI, AMC, Lahore, Pakistan
2. Ambreen Gul: HITEC Institute of Medical Sciences, Taxila, Pakistan
3. Muhammad Shoaib: Khwaja Muhammad Safdar Medical College, Sialkot, Pakistan
4. Tanvir Ali Khan Shirwany: CMH Institute of Medical Sciences, Bahawalpur, Pakistan
Abstract:
OBJECTIVES: To compare the serum levels of visfatin in non-obese normotensives, non-obese hypertensives and obese hypertensives. STUDY DESIGN: A comparative cross sectional study. PLACE AND DURATION: At Physiology Department, Postgraduate Medical Institute, Lahore in collaboration with Services Institute of Medical Sciences, Lahore, from November 1st, 2013 to October 30th, 2014. METHODOLOGY: The study included 81 subjects divided into three groups of 27 each i.e. non-obese normotensives, non-obese hypertensives and obese hypertensives. Blood pressure levels, Body Mass Index (BMI) and Waist to Hip Ratio (WHR) were measured. Fasting blood samples were collected to estimate serum visfatin level. RESULTS: Mean serum visfatin levels of 70.97±50.30 ng/ml were observed in the obese hypertensive patients while 33.71±10.66 ng/ml and 5.21±3.57 ng/ml was found in the non-obese hypertensives and non-obese normotensives, respectively. CONCLUSION: Serum Visfatin levels can be used as biomarker for the evaluation of hypertension in obese and non-obese patients.
Page(s): 233-237
DOI: DOI not available
Published: Journal: Isra Medical Journal, Volume: 9, Issue: 4, Year: 2017
Keywords:
Keywords are not available for this article.
References:
[1] ChobanianAV,BakrisGL,BlackHR,CushmanWC,GreenLA,IzzoJL, 2003.Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure,Hypertension 42 1206 -52
[2] IqbalR,AhmadZ,MalikF,MahmoodS,ShahzadiN,MehwishS, 2012.A statistical analysis of hypertension as cardiovascular risk factor,Middle East J Sci Res 12 19 -22
[3] CossioY,AlexanderS, 2007.Human physiology: From cells to systems, 382 -
[4] MalpasSC, 2010.Sympathetic nervous system overactivity and its role in the development of cardiovascular disease,Physiol Rev 90 513 -57
[5] D'Agostino,RB , Vasan,RS , Pencina,MJ , Wolf,PA , Cobain,M , Massaro,JM, 2008.General cardiovascular risk profile for use in primary care the Framingham Heart Study,Circulation 117 743 -53
[6] World Health Organization (WHO). Global database on body mass index. BMI classification. 2013, (Cited date: 29 July 2017) Website: [ http://apps.who.int/bmi/ ]. -
[7] RomeroR,BonetJ,De La SierraA,AguileraMT, 2007.Undiagnosed obesity in hypertension: clinical and therapeutic implications,Blood Pressure 16 347 -53
[8] HallJE,KuoJJ,da SilvaAA,de PaulaRB,LiuJ,TallamL, 2003.Obesity-associated hypertension and kidney disease,Curr Opin Nephrol Hypertens 12 195 -200
[9] KumanyikaSK,ObarzanekE,StettlerN,BellR,FieldAE,FortmannSP, 2008.Population-based prevention of obesity,Circulation 118 428 -64
[10] ShaheenA,NazliR,FatimaS,AliR,KhanI,KhattakS. Adipokine, 2016.Serum visfatin level in pregnancy induced hypertension and uncomplicated pregnancy,Pak J Med Sci 32 1419 -24
[11] SonoliSS,ShivprasadS,PrasadCV,PatilAB,DesaiPB,SomannavarMS, 2011.Visfatin - a review,Eur Rev Med Pharmacol Sci 15 9 -14
[12] TaskesenD,KirelB,UsT., 2012.Serum visfatin levels, adiposity and glucose metabolism in obese adolescents,J Clin Res Pediatr Endocrinol 4 76 -81
[13] GuzikTJ,MangalatD,Korbut R. Adipocytokines, 2006.- novel link between inflammation and vascular function?,J Physiol Pharmacol 57 505 -28
[14] RotkegelS,ChudekJ,Spiechowicz-ZatonU,FicekR,AdamczakM, 2013.Wiecek A. The Effect of Sodium Restricted Diet on Plasma Visfatin Levels in Hypertensive Patients with Visceral Obesity, 37 124 -31
[15] MuJ,FengB,YeZ,YuanF,ZengW,LuoZ, 2011.Visfatin is related to lipid dysregulation, endothelial dysfunction and atherosclerosis in patients with chronic kidney disease,J Nephrol 24 177 -84
[16] TaddeiS,VirdisA,GhiadoniL,SudanoI,SalvettiA, 2001.Endothelial dysfunction in hypertension,J Cardiovasc Pharmacol 38 11 -14
[17] RezkMY, 2014.Visfatin and cardiovascular protection,Journal of Drug Delivery and Therapeutics 4 154 -66
[18] LimSY,DavidsonSM,ParamanathanAJ,SmithCC,YellonDM,Hausenloy DJ, 2008.The novel adipocytokine visfatin exerts direct cardioprotective effects,J Cell Mol Me 12 1395 -1403
[19] 2017.Waist circumference and waist-hip ratio: Report of a WHO expert consultation,[Retrieved on 29 July 8 -
[20] GunesF,AkbalE,CakirE,AkyurekO,AltunbasM,OzbekM., 2011.Visfatin may be a novel marker for identifying stages of essential hypertension in advanced age patients,Intern Med 51 553 -57
[21] OzalE,SahinI,BolatI,PusurogluH,AvciII,AkgulO, 2017.Visfatin levels are increased in patients with resistant hypertension and are correlated with left ventricular hypertrophy,Blood Pressure Monitoring 22 137 -42
[22] DogruT,SonmezA,TasciI,YilmazMI,ErdemG,ErturkH, 2007.Plasma visfatin levels in young male patients with uncomplicated and newly diagnosed hypertension,J Hum Hypertens 21 173 -75
[23] BalistreriCR,CarusoC,CandoreG., 2010.The role of adipose tissue and adipokines in obesity-related inflammatory diseases,Mediat Inflamm 1 -9
[24] Rui-zhenLI,Xin-yuMA,Hui-lingLU,HuiYAO,Shou-kangCHEN,Si-xiuKANG, 2013.Study of visfatin, ASP level in obese children and their clinical significance,Int J Pediatr Oncol 40 -
[25] GoktasZ,WangS, 2012.Visfatin and RBP4 gene expression levels in different adipose tissues and insulin resistance,In: BMC Proceedings 6 1 -17
[26] HaiderDG,SchallerG,KapiotisS,MaierC,LugerA,WolztM., 2006.The release of the adipocytokine visfatin is regulated by glucose and insulin,Diabetologia 49 1909 -14
[27] WangP,DuH,ZhangRY,GuanYF,XuTY,XuQY, 2010.Circulating and local visfatin/Nampt/PBEF levels in spontaneously hypertensive rats, stroke-prone spontaneously hypertensive rats and Wistar-Kyoto rats,J Physiol Sci 60 317 -24
[28] BerndtJ,KlötingN,KralischS,KovacsP,FasshauerM,SchönMR, 2005.Plasma visfatin concentrations and fat depot-specific mRNA expression in humans,Diabetes 54 2911 -16
Citations
Citations are not available for this document.
0

Citations

0

Downloads

2

Views